Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide

Cancer Science

Volumn 101, Issue 10, 2010, Pages 2214-2219

  Mizutani, Hideki ^a,b   Hiraku, Yusuke ^c   Tada Oikawa, Saeko ^c,d   Murata, Mariko ^c   Ikemura, Kenji ^a,b   Iwamoto, Takuya ^b   Kagawa, Yoshiyuki ^b,e   Okuda, Masahiro ^b   Kawanishi, Shosuke ^c,f  

^a KINJO GAKUIN UNIVERSITY   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^e UNIVERSITY OF SHIZUOKA   (Japan)

^f SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; GLUTATHIONE; HISTONE DEACETYLASE; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; ROMIDEPSIN; SUPEROXIDE; TRICHOSTATIN A; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

APOPTOSIS; ARTICLE; CELL FREE SYSTEM; CELL STRAIN CACO 2; CELL STRAIN HL 60; CYTOTOXICITY; DNA DETERMINATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; TUMOR CELL; DRUG EFFECTS; METABOLISM; TUMOR CELL LINE;

ACETYLCYSTEINE; APOPTOSIS; CELL LINE, TUMOR; DEPSIPEPTIDES; GLUTATHIONE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROGEN PEROXIDE; HYDROXAMIC ACIDS;

EID: 77957023872     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01645.x     Document Type: Article

References (34)

1. Ueda H, Nakajima H, Hori Y. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No 968. I, Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994, 47:301-10.
2. Ueda H, Manda T, Matsumoto S. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994, 47:315-23.
3. Schrump DS, Fischette MR, Nguyen DM. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res 2008, 14:188-98.
4. Piekarz RL, Frye R, Turner M. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009, 27:5410-7.
5. Doi S, Soda H, Oka M. The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther 2004, 3:1397-1402.
6. Peart MJ, Tainton KM, Ruefli AA. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003, 63:4460-71.
7. Vinodhkumar R, Song YS, Devaki T. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. Biomed Pharmacother 2008, 62:85-93.
8. Ruefli AA, Ausserlechner MJ, Bernhard D. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001, 98:10833-8.
9. Lucas DM, Davis ME, Parthun MR. The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 2004, 18:1207-14.
10. Rosato RR, Almenara JA, Maggio SC. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells. Mol Cancer Ther 2005, 4:1772-85.
11. Martirosyan A, Leonard S, Shi X, Griffith B, Gannett P, Strobl J. Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. J Pharmacol Exp Ther 2006, 317:546-52.
12. Inoue T, Kato K, Kato H. Level of reactive oxygen species induced by p21Waf1/CIP1 is critical for the determination of cell fate. Cancer Sci 2009, 100:1275-83.
13. Adachi M, Zhang Y, Zhao X. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin Cancer Res 2004, 10:3853-62.
14. Choudhary S, Wang HC. Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction. J Cancer Res Clin Oncol 2009, 135:1601-13.
15. Mizutani H, Tada-Oikawa S, Hiraku Y, Oikawa S, Kojima M, Kawanishi S. Mechanism of apoptosis induced by a new topoisomerase inhibitor through the generation of hydrogen peroxide. J Biol Chem 2002, 277:30684-9.
16. Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M, Kawanishi S. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 2005, 76:1439-53.
17. Tada-Oikawa S, Oikawa S, Kawanishi M, Yamada M, Kawanishi S. Generation of hydrogen peroxide precedes loss of mitochondrial membrane potential during DNA alkylation-induced apoptosis. FEBS Lett 1999, 442:65-9.
18. Murata M, Suzuki T, Midorikawa K, Oikawa S, Kawanishi S. Oxidative DNA damage induced by a hydroperoxide derivative of cyclophosphamide. Free Radic Biol Med 2004, 37:793-802.
19. Kawanishi S, Hiraku Y. Amplification of anticancer drug-induced DNA damage and apoptosis by DNA-binding compounds. Curr Med Chem Anticancer Agents 2004, 4:415-9.
20. Iwamoto T, Hiraku Y, Kojima M, Kawanishi S. Amplification of C1027-induced DNA cleavage and apoptosis by a quinacrine-netropsin hybrid molecule in tumor cell lines. Arch Biochem Biophys 2005, 434:232-40.
21. Kasugai I, Yamada M. Adaptation of human leukemia HL-60 cells to hydrogen peroxide as oxidative stress. Leuk Res 1989, 13:757-62.
22. Kasugai I, Yamada M. High production of catalase in hydrogen peroxide-resistant human leukemia HL-60 cell lines. Leuk Res 1992, 16:173-9.
23. Hiraku Y, Kawanishi S. DNA damage and apoptosis induced by benzene metabolites. Cancer Res 1996, 56:5172-8.
24. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1β-converting enzyme-like proteases. Proc Natl Acad Sci USA 1996, 93:14559-63.
25. Decaudin D, Geley S, Hirsch T. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 1997, 57:62-7.
26. Murata M, Moriya K, Inoue S, Kawanishi S. Oxidative damage to cellular and isolated DNA by metabolites of a fungicide ortho-phenylphenol. Carcinogenesis 1999, 20:851-7.
27. Emanuele S, Lauricella M, Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications. Int J Oncol 2008, 33:637-46.
28. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009, 107:600-8.
29. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459-68.
30. Chen J, Bai H, Wang C, Kang J. Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells. Pharmazie 2006, 61:710-6.
31. Donadelli M, Costanzo C, Beghelli S. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 2007, 1773:1095-106.
32. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997, 18:44-51.
33. Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 2000, 29:323-33.
34. Furumai R, Matsuyama A, Kobashi N. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002, 62:4916-21.